NMD4C Pre-clinical Science Pillar Seeking Trainee Input
The NMD4C cell and animal-based task groups are actively seeking the input of neuromuscular trainees to help inform our activities, including:
- Facilitating training and lab exchanges for trainees
- Organizing a summer school to train basic researchers
- Creating and maintaining a database of Canadian research lab expertise (techniques, cell/animal lines, models etc.)
If you are willing to participate in a committee that will meet periodically to share input on NMD4C cell and animal-based research activities, we want to hear from you!
To register your interest, please complete our short (1-2 min) survey here to be contacted with more information. If you are a senior researcher, please feel free to complete the survey yourself and/or share it with the trainees in your lab!
For further information on this opportunity or for specific questions, please contact network coordinaor James Davis at .
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.